Business Wire

Pyramid Analytics Expands UK Presence With Launch of Public Sector Practice

15.9.2022 04:46:00 EEST | Business Wire | Press release

Share

Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today announced the launch of a UK Public Sector Practice. The new division will bring the transformational power of augmented analytics to public departments, agencies and public bodies across the United Kingdom. Decision Intelligence enabled by AI and machine learning can modernize the delivery of critical public services, including healthcare, utilities, and transportation in Europe’s largest public sector market. There are 23 ministerial departments, 20 non-ministerial departments, 417 agencies and other public bodies, and 14 public corporations in the UK1.

Key Points:

  • The Guardian reported that UK government spending on technology R&D is estimated to reach £14.9 billion for 2021 and 2022, and the government aims to increase this to £22 billion by 2026–27.
  • The UK Public Sector practice will be led by Alastair Roriston, an experienced leader of successful programmes to connect technology with the needs of government agencies.
  • Pyramid has a long track record of enabling technology innovation in the public sector. Government customers include the United States Department of Veterans Affairs, Israel Aerospace Industries, Israel Defense Forces, Ministry of Defence of the Republic of Slovenia, and Statistics Finland.
  • The Pyramid Decision Intelligence Platform, training and services will be provided directly and through partnerships.
  • Decision Intelligence will help frontline public sector workers to make faster and more informed decisions, elevating the level of service for the general public.

A New Future for the UK Public Sector

The COVID-19 pandemic accelerated digital transformation across all sectors of the economy and society, and government needs to keep pace. Spearheaded with a clear mandate from Cabinet Office, the UK government is leading the way in reimagining how data can be used to improve the operations of the public sector and the standard of service they offer to ordinary people every day.

NHS England unveiled plans in April to develop a federated data platform (FDP), with an estimated procurement value of £240 million. According to the notice, the FDP will be “an ecosystem of technologies and services” and “an essential enabler to transformational improvements across the NHS”. It will be built around five major use cases: population health and person insight, care co-ordination, elective recovery, vaccines and immunisation, and the supply chain.

Pyramid Experience with Massive Public Healthcare Systems

The Pyramid Decision Intelligence Platform is currently used by the United States Department of Veteran Affairs (VA), a Cabinet-level executive branch department of the federal government charged with providing life-long healthcare services to eligible military veterans at the 170 medical centers and outpatient clinics located throughout the country. The VA provides comprehensive healthcare services to 9 million veterans.

The Pyramid Decision Intelligence Platform is used by clinical, medical and administrative staff to identify patterns and execution gaps across the system, ensuring US military veterans receive more personalised and enhanced care. So far, a programme run by just three people has trained 40,000 staff in the use of the platform, with plans to eventually equip 60,000 to start using Decision Intelligence to improve the services they offer to US military veterans and their families.

Decision Intelligence is the Next Big Data Analytics Innovation

The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.

The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.

Quotes

Tom Warren , Regional Managing Director, UKI, Pyramid Analytics:

“The Pyramid family are excited to announce this next chapter of our story. We look forward to enabling the digital transformation of UK public sector organisations, helping to deliver better, faster and more efficient services to those who need them the most. We hope to use Decision Intelligence to turn data analytics in the public sector from the complex to the simple with decision intelligence.

“I am excited to be working with the highly experienced and forward-thinking Alastair Roriston to advance Pyramid’s expansion into the UK public sector. He joins an already successful and high-performing team, who have been instrumental to Pyramid’s expansion in the UKI. With Alastair’s expertise, the sky is the limit.”

Alastair Roriston , Director of Sales UK Public Sector, Pyramid Analytics:

“I am thrilled to have joined this innovative and ground-breaking company and even keener to assist in its expansion into the UK public sector. Throughout my career, I have seen the huge positive impact when the essential work of the public sector is married to the cutting-edge possibilities of technology – the opportunity for change is nearly limitless.

“I truly believe that Pyramid’s decision intelligence platform will revolutionise how government and public sector organisations deliver their digital and online services. Far too often, the wheels of public services are held up by siloed systems and antiquated approaches to data. A doctor should not have to wait precious minutes or hours for reports and patient data to arrive. Why should they not have that information and advice on next steps available in moments? Decision intelligence can eliminate these inefficiencies, making every frontline public sector worker a citizen data scientist with a world of dynamic, augmented analytics at their fingertips.”

About Pyramid Analytics

Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.

1 GOV.UK

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

UK
Alex Izza
Resonance
+44 (0) 759 189 9654
pyramidanalytics@resonancecrowd.com

US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com

Chas Kielt
Vice President of Global Corporate Communications, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye